Source:http://linkedlifedata.com/resource/umls/id/C0246203
PDQ: The sodium salt of a synthetic lipid-lowering agent with potential antineoplastic properties. Fluvastatin competitively inhibits hepatic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses through the suppression of MHC II (major histocompatibility complex II) on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. Due to anti-inflammatory effects mediated by their alterations of lipid metabolism, statins may possess chemopreventive and therapeutic antineoplastic properties. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=487588&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=487588&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.